» Articles » PMID: 16456618

Unfaithfulness and Promiscuity of a Mutant Androgen Receptor in a Hormone-refractory Prostate Cancer

Overview
Publisher Springer
Specialty Biology
Date 2006 Feb 4
PMID 16456618
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Missense mutations in the androgen receptor (AR) contribute to the failure of hormonal therapy for prostate cancer (PCa), but the underlying molecular bases remain uncharacterized. Here, we describe a new AR variant found in a hormone-refractory metastatic PCa, in which threonine 575 in the DNA binding domain, and threonine 877 in the ligand-binding domain, were both replaced by an alanine. Using gene reporter assays, we demonstrate that the T575A mutation weakened transcriptional activity from promoters containing AR-specific responsive elements, while activity from promoters with AR-non-specific elements was enhanced. Data from gel shift experiments revealed a preferential binding of the T575A mutant to AR-non-specific motifs. We demonstrate that the two mutations T575A and T877A cooperate to confer new functional properties on the AR, and that the mutant AR functions simultaneously as a promiscuous AR due to the T877A mutation, and an unfaithful AR due to the T575A mutation.

Citing Articles

The evolution and polymorphism of mono-amino acid repeats in androgen receptor and their regulatory role in health and disease.

Meszaros A, Ahmed J, Russo G, Tompa P, Lazar T Front Med (Lausanne). 2022; 9:1019803.

PMID: 36388907 PMC: 9642029. DOI: 10.3389/fmed.2022.1019803.


Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.

Cai Z, Chen W, Zhang J, Li H Int Urol Nephrol. 2018; 50(10):1753-1764.

PMID: 30128923 DOI: 10.1007/s11255-018-1964-0.


Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Lallous N, Volik S, Awrey S, Leblanc E, Tse R, Murillo J Genome Biol. 2016; 17:10.

PMID: 26813233 PMC: 4729137. DOI: 10.1186/s13059-015-0864-1.


Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Lorente D, Mateo J, Zafeiriou Z, Smith A, Sandhu S, Ferraldeschi R Nat Rev Urol. 2015; 12(1):37-47.

PMID: 25563847 DOI: 10.1038/nrurol.2014.345.


Androgen receptor gene mutation, rearrangement, polymorphism.

Eisermann K, Wang D, Jing Y, Pascal L, Wang Z Transl Androl Urol. 2014; 2(3):137-147.

PMID: 25045626 PMC: 4101814. DOI: 10.3978/j.issn.2223-4683.2013.09.15.